The EGFRxHER2 T-BsAb mediated cytotoxicity against EGFR-KO and HER2-KO lines with sensitivities comparable to the ‘tumor monovalent’ T-BsAbs HER2xCD33 and EGFRxCD33 respectively (Fig. 6B; Table 4). This evidence concerns the gene EGFR and neoplasm.